Close

What are ADC's

Our services

ADC Review
is made possible by:




Calicheamicin

Calicheamicin (also known as LL-E33288 antibiotics) was first discovered in the mid-1980s by a scientist from American Cyanamid Company’s medical research division, Lederle Laboratories (now Pfizer) while on vacation in Kerrville, Texas (USA).

The scientist collected a soil sample, which consisted of caliche clay, and sent it back to the lab for testing. In the lab scientists grew a culture of the chalky soil sample and found that a tiny bacterium (Micromonospora echinospora ssp. calichensis ) within the sample produced a compound that was found to be an incredibly potent cytotoxic agent. [1] [*]calicheamicin G_2

Bergman cyclization
The researchers noted that the new compound called calicheamicin worked by destroying the DNA of cancer cells. Its Mechanism of Action is based on a strong reaction when it gets in contact with DNA. This reaction, known as the Bergman cyclization, results in cleaving the DNA and thus destroying the cancer cell. [2]

Calicheamicin is so potent (between 1,000 to 10,000 times more cytotoxic to normal cells than anticancer drugs already on the market. With optimal dose at 0.5–1.5 μg/k calicheamicin, it is approximately 4,000 times more active than doxorubicin) that it also destroys the DNA of normal cells and, as a result, cannot not be used as a single agent to treat patients.

Furthermore, in biochemical induction assays at concentrations below 1 pg/mL calicheamicin is extremely active against Gram-positive bacteria and also highly active against Gram-negative bacteria

In one study transcriptional effects were observed as early as 2 min into drug exposure.[3] Among these effects were the upregulation of two nuclear proteins encoding a Y’-helicase (a subtelomerically encoded protein whose function is to maintain telomeres) and a suppressor of rpc10 and rpb40 mutations (both rpc10 and rpb40 encode RNA polymerase subunits). The researchers noted that with longer calicheamicin exposure, genes involved in chromatin arrangement, DNA repair and/or oxidative damage, DNA synthesis and cell cycle checkpoint control as well as other nuclear proteins were all differentially expressed. Furthermore, ribosomal proteins and a variety of metabolic, biosynthetic, and stress response genes were also altered in their expression. [3]

Linking with monoclonal antibodies
George Ellestad, Janis Upeslacis and Philip Hamann (Wyeth Research; Pearl River, NY, now Pfizer) began studying calicheamicin in order to better understand its mechanism. Together, they devised a plan to link calicheamicin to a monoclonal antibody that specifically targeted cancer cells. In this way, they were able to limit harming healthy cells, while the linked antibody took the highly potent calicheamicin directly to the tumor cell.

In 2004 Ellestad, Upeslacis and Hamann were honored by the American Chemical Society for their contribution to the isolation and structural elucidation of the calicheamicin family of enediynes, including calicheamincin, the antitumor antibiotic that formed the basis of gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth).

A new class of drugs
On May 17, 2000, almost 20 years after its discovery, the U.S. Food and Drug Administration (FDA) approved gemtuzumab ozogamicin, the first monoclonal antibody-drug conjugate or ADC linking calicheamicin to a monoclonal antibody. The drug consists of N-acetyl-γ-calicheamicin covalently attached to the humanized anti-CD33 IgG4 κ antibody (hP67.6) via a bifunctional linker (with a DAR of 2 – 3 molecules of calicheamicin per molecule of mAb).[4]

Upon internalization of gemtuzumab ozogamicin, the calicheamicin prodrug is released by hydrolysis of the hydrazone in the lysosomes of the CD33+ target cells.  The enediyne drug is then activated by reductive cleavage of the disulfide bond. In order to prevent premature release of calicheamicin by circulating reduced thiols, such as glutathione, the disulfide linkage is stabilized by two methyl groups close to the disulfide.[4]

Gemtuzumab ozogamicin was the very first drug in its class (antibody-targeted chemotherapy agents) and is used in the treatment of acute myelogenous leukemia (AML), a virulent and often fatal form of cancer in which certain white blood cells become cancerous and rapidly accumulate in the bone marrow, preventing normal marrow from growing and functioning properly. It is among the most serious forms of adult leukemia, with a relatively high fatality rate. Gemtuzumab ozogamicin specific antibody recognizes CD33, a cell-surface molecule which is abundant on AML cells but absent from normal blood stem cells, the seeds from which normal blood and immune cells originate. [5]

Post marketing – and follow-up trials
Pfizer voluntarily pulled gemtuzumab ozogamicin from the market in 2010 due to post-marketing evidence of lack of efficacy, as well as unacceptable toxicity. However, in ongoing clinical trials, Sylvie Castaigne, MD, of the Hôpital de Versailles in France, and lead investigator from the Acute Leukemia French Association (ALFA) study, and her colleagues, are using a fractionated dosing regimen for gemtuzumab ozogamicin. Instead of using the standard dose of 9mg/m2, which does not allow the drug to be used in combination with conventional chemotherapy, the researchers dose the drug in three increments of 3mg/m2 over a week’s time, which enables a combination with chemotherapy. The results show that this altered regimen limits toxicity and boost overall efficacy. The researchers also noted that overall adverse events were substantially lower than those historically observed with the standard, single dose infusion of gemtuzumab ozogamicin.

The trial included 278 AML patients, ages 50-70 years, who were randomized to one of two treatment arms of standard chemotherapy (60 mg/m2 of daunorubicin for three days and 200 mg/m2 of cytarabine for seven days) with or without fractionated gemtuzumab ozogamicin. Patients were followed for three years. The results showed that the median event-free survival time was 19.6 months in the gemtuzumab ozogamicin arm vs 11.9 months in the chemotherapy alone arm. Overall survival was also improved significantly in the Gemtuzumab ozogamicin arm, with a median overall survival of 34 months vs 19.2 months in the chemotherapy alone arm.

[*] Calicheamicin is part of a class of toxic chemicals called Alkynes, which are generally not very useful as pharmaceuticals. However, specific Alkynes known as enediynes possess a very strong and aggressive anti-tumor compound. These molecules are cyclic and contain an alkene (double bond) in between two alkyne (triple bonds) functions, therefore the name ene < alkene and diyne < two alkynes.


References:
[1] Maiese WM, Lechevalier MP, Lechevalier HA, Korshalla J, Kuck N, Fantini A, Wildey MJ, Thomas J, Greenstein M.Calicheamicins, a novel family of antitumor antibiotics: taxonomy, fermentation and biological properties. J Antibiot (Tokyo). 1989 Apr;42(4):558-63.
[2] Basic Organic Chemistry, 2012
[3] Watanabe CM, Supekova L, Schultz PG. Transcriptional effects of the potent enediyne anti-cancer agent Calicheamicin gamma(I)(1).Chem Biol. 2002 Feb;9(2):245-51
[4] Dosio F , Brusa P, Cattel L Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components  Toxins 2011, 3, 848-883
[5] Ricart AD, Tolcher AW. Technology insight: cytotoxic drug immunoconjugates for cancer therapy. Nat Clin Pract Oncol. 2007;4:245-255


Last Editorial Review: March 20, 2015

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

ADCs – Look Forward to a Potent Future

27 September, 2018

Antibody-drug conjugation (ADC) technology has been around for several decades but has yet to reach its full potential in terms of clinical success. In this second article, Penelope Drake and David Rabuka, of...


Skip to toolbar